Penumbra PEN 深 沪
已收盘 07-10 16:00:00 美东时间
318.10
+0.150
+0.05%
华盛通- 最 高318.51
- 今 开318.24
- 成交量 14.66万股
- 最 低 317.3501
- 昨 收 317.95
- 总市值 125.11亿
- 52周最高 362.41
- 市盈率 静 70.34
- 换手率 0.37%
- 52周最低 221.26
- 委 比 17.65%
- 总股本 3933.14万
- 历史最高 362.41
- 量 比 0.54
- 振 幅 0.36%
- 历史最低 35.315
- 每 手 1
- 风险率 38.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Penumbra enrolls first patient in FORWARD distal stroke thrombectomy study
Penumbra enrolls first patient in FORWARD distal stroke thrombectomy study Penumbra launched the FORWARD clinical study in distal acute ischemic stroke, enrolling its first patient in the trial. Prospective, real-world, multi-center study targets up to 250 patients across about 40 sites evaluating m
07-07 21:15
Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer assisted vacuum thrombecto...
07-07 21:11
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds details of Vertex deal in paragraphs 1 and table July 7 (Reuters) - Vertex Pharmaceuticals VRTX.O has agreed to buy Crinetics Pharmaceuticals CRNX.O for about $10 billion , expanding its reach beyond blood disorders a
07-07 18:08
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $320
Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and lowers the price target from $335 to $320.
07-07 00:51
微软、埃克森美孚与戴尔热门股票报告
2026年6月30日扎克斯研究日报从当日发布的约70份报告中精选16只重点股票研究内容，覆盖微软、埃克森美孚、戴尔、微型市值股BK科技等标的，同步推出盘前发布的...
07-01 05:41
Record-setting healthcare M&A activity to extend through H2: PwC
Healthcare dealmaking is already at the highest level since the pandemic, and the momentum is expected to continue into H2 2026, driven by looming patent cliffs and consumer demand for areas such as w...
06-26 01:59
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
